Cyclobutenedione compounds

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S317000, C514S300000, C514S320000, C514S322000, C514S323000, C546S113000, C546S196000, C546S199000, C546S201000, C546S229000, C546S236000

Reexamination Certificate

active

06696469

ABSTRACT:

BACKGROUND OF THE INVENTION
The compounds of the present invention are useful in the treatment of diseases or pathological conditions in which endothelial dysfunction is known to be a pathogenic and/or aggravating mechanism. Such pathologies are: atherosclerosis, the existence of vascular risk factors (dyslipidaemia, diabetes, systemic arterial hypertension), the various clinical forms of myocardial or peripheral ischaemia, cardiac insufficiency and the various forms of pulmonary arterial hypertension. The said compounds are also useful in the treatment of patients undergoing heart transplantation or vascular repermeabilisation, such as a bypass, thrombolysis or arterial dilatation with or without a stent.
A reduction in the vascular availability of nitrogen monoxide (NO) constitutes the major mechanism of endothelial dysfunction observed in the diseases and pathological conditions mentioned above and explains its pathogenic role (
Cardiovasc. Res.,
1999, 43, 572
; Coronary. Art. Dis.
1999, 10 277
; Coronary. Art. Dis.,
1999, 10, 301
; Coronary. Art. Dis.,
1999, 10, 287
; Coronary. Art. Dis.,
1999, 10, 295).
In the said pathological conditions, the endothelial dysfunction may in fact result from two main mechanisms: 1) inadequate production of NO associated with inhibition of endothelial NO synthase by endogenous inhibitors, such as ADMA (asymmetric dimethyl-arginine), the plasma concentration of which increases in patients exhibiting cardiovascular risk factors (
Cardiovasc. Res.,
1999, 43, 542
; Hypertension,
1997, 29, 242
; Circulation,
1997, 95, 2068), 2) inactivation of the NO by the superoxide anion (O
2

), the production of which is increased in pathological conditions (
Cardiovasc. Res.,
1999, 43, 562
; Eur.J Biochem.
1997, 245, 541
; J. Clin. Invest.,
1993, 91 2546).
Under normal conditions, NO produces major effects such as: 1) regulation of arterial vasomotricity by means of its vasodilator effect (
N Engl. J Med.,
1993, 329, 2002
; Nature,
1980, 288, 373), 2) limitation of platelet adhesion and aggregation (
Trends Pharmacol. Sci.,
1991, 12, 87), 3) control of the adhesion of leukocytes and monocytes to endothelial cells (
Proc. Natl Acad. Sci. USA,
1991, 88, 4651), 4) inhibition of the proliferation of vascular smooth muscle cells (
Cardiovasc. Res.,
1999, 43, 580
, Circulation,
1993, 87 V51), which explains why the deficiency of NO in the arterial wall is favourable to pathological phenomena, such as vasoconstriction, thrombosis, lipid accumulation and proliferation of vascular smooth muscle cells.
In vitro experiments have enabled it to be shown that the compounds of the present invention are capable of limiting the endothelial dysfunction and reduced vascular availability of NO that were induced by tests involving the two physiopathological mechanisms already mentioned: inhibition of endothelial NO synthase and oxidative stress due to production of O
2

.
Besides the fact that they are new, the compounds of the present invention, by virtue of their specific pharmacological activity, which is capable of limiting the development of endothelial dysfunction, are useful in preventing the development, extension and complications of atherosclerotic lesions, especially in patients exhibiting a vascular risk factor (dyslipidaemia, diabetes, arterial hypertension), and in treating the various clinical forms of myocardial or peripheral ischaemia, cardiac insufficiency and the various forms of pulmonary arterial hypertension. The compounds are also used for preventing vascular complications (spasm, thrombosis, restenosis, accelerated atherosclerosis) in patients undergoing a bypass, vascular dilatation with or without a stent or other forms of vascular repermeabilisation and also heart transplantation.
DETAILED DESCRIPTION OF THE INVENTION
More specifically, the present invention relates to compounds of formula (I):
wherein:
X represents:
a monocyclic or bicyclic, saturated, partially unsaturated or aromatic heterocycle, having from 5 to 12 ring members, containing from 1 to 3 hetero atoms selected from oxygen, nitrogen and sulphur but containing at least one nitrogen atom, said heterocycle being bonded to the remainder of the molecule by said nitrogen atom, and said heterocycle being optionally substituted,
or a group of formula —NR
2
R
3
wherein R
2
represents a hydrogen atom or a linear or branched (C
1
-C
6
)alkyl group, and R
3
represents an aryl group optionally substituted, a 1,3-dihydro-2H-benzimidazolyl-2-one group, or a linear or branched (C
1
-C
6
)alkyl group substituted by a monocyclic or bicyclic, saturated, partially unsaturated or aromatic heterocycle, having from 5 to 12 ring members, containing from 1 to 3 hetero atoms selected from oxygen, nitrogen and sulphur but containing at least one nitrogen atom, said heterocycle being optionally substituted,
n in represents zero or 1,
R
1
represents a hydrogen atom or a linear or branched (C
1
-C
6
)alkyl group,
Ra represents a single bond or a linear or branched (C
1
-C
6
)alkylene chain,
A represents a nitrogen atom or a CH group, but A represents only a CH group when Ra represents a single bond, and A represents only a nitrogen atom when n represents zero,
E represents a nitrogen atom or a CRe group wherein Re represents either a hydrogen atom, or a bond to a carbon atom of W, it being understood that at least one of the groups A and E represents a nitrogen atom,
Rb represents a single bond or a linear or branched (C
1
-C
6
)alkylene chain, one of the carbon atoms of which is optionally replaced by an oxygen atom or a sulphur atom,
W represents an aryl or heteroaryl group, each of those groups being optionally substituted,
their optical isomers, their hydrates, their solvates and addition salts thereof with a pharmaceutically acceptable acid, it being understood that:
“aryl group” is understood to mean a group selected from phenyl, biphenyl, bicyclo[4.2.0]octa-1,3,5-trienyl, naphthyl, dihydronaphthyl, tetrahydronaphthyl, indanyl and indenyl,
“heteroaryl group” is understood to mean an aryl group as defined above containing from 1 to 3 identical or different hetero atoms selected from oxygen, nitrogen and sulphur,
“optionally substituted”, when associated with “heterocycle”, “aryl group” or “heteroaryl group”, is understood to mean optionally substituted by one or more identical or different groups selected from halogen, linear or branched (C
1
-C
6
)alkyl, hydroxy, linear or branched (C
1
-C
6
)alkoxy, mercapto, linear or branched (C
1
-C
6
)alkylthio, linear or branched (C
1
-C
6
)trihaloalkyl, cyano, nitro, amino, linear or branched (C
1
-C
6
)-alkylamino, dialkylamino in which each alkyl moiety has from 1 to 6 carbon atoms and is linear or branched, and methylenedioxy,
“optical isomers” are understood to mean the enantiomers and diastereoisomers.
Among the pharmaceutically acceptable acids, there may be mentioned by way of non-limiting example hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, acetic acid, trifluoroacetic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, tartaric acid, maleic acid, citric acid, ascorbic acid, oxalic acid, methanesulphonic acid, camphoric acid.
The compounds of the invention are preferably the compounds of formula (IA):
wherein X, R
1
, Ra, A, E, Rb and W are as defined for formula (I).
According to an advantageous embodiment of the invention, the preferred compounds are the compounds of formula (I) wherein X represents a heterocycle as defined for formula (I).
According to another advantageous embodiment, the preferred compounds of the invention are the compounds of formula (I) wherein X represents a group of formula —NR
2
R
3
as defined for formula (I).
Especially advantageously, the preferred compounds of the invention are the compounds of formula (I) wherein X represents a 1-indolinyl or 2,3-dihydro-1H-pyrrolo[2,3-c]pyridin-1-yl group, each of those groups being optionally substituted by one or more groups as defined for formula (I).
Also especially adva

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Cyclobutenedione compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cyclobutenedione compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclobutenedione compounds will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3344283

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.